Background: Oral chemotherapy agents are frequently compounded in veterinary medicine however, the potency of some formulations have been shown to vary from that of Food and Drug Administration (FDA)-approved products. Aims: The objective of this study was to evaluate the potency and stability of three compounded oral chemotherapeutics commonly prescribed to be administered over time. Materials & Methods: Compounded chlorambucil 1 mg, cyclophosphamide 5 mg and melphalan 1 mg were obtained and for potency tested upon receipt and 6 weeks later. Results: Potency ranged from 71 to 104% for chlorambucil and 58 to 109% for melphalan; 1/4 and 2/4 samples were <90% of labelled strength at baseline and 6 weeks, respectively, for both drugs. Potency of cyclophosphamide ranged from 92 to 107% with all samples +/−10% of labelled strength at all time points. Discussion/Conclusion: These results demonstrate variability of compounded chemotherapy products, and highlight the need to consider both potency and stability when prescribing orally compounded chemotherapy.
|Number of pages||6|
|Journal||Veterinary and Comparative Oncology|
|State||Published - Dec 2017|
Bibliographical noteFunding Information:
This work was completed at and supported by the Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis. Dr. J.H.B. is supported by the National Cancer Institute of the National Institutes of Health under Award Number K12CA138464. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2017 John Wiley & Sons Ltd
ASJC Scopus subject areas
- Veterinary (all)